Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Xueying Tan, Xiaojing Cao, Minzhi Zhou, Ping Zou & Jingbo Hu. (2017) Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs 26:9, pages 1083-1089.
Read now
Read now
Stuart A. Ross. (2015) A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes. Current Medical Research and Opinion 31:1, pages 125-135.
Read now
Read now
Articles from other publishers (20)
Dalia A. Ali, Laura Domínguez Mercado, Brandon L. Findlay, Antonella Badia & Christine DeWolf. (2022) Opposites Attract: Electrostatically Driven Loading of Antimicrobial Peptides into Phytoglycogen Nanocarriers. Langmuir 39:1, pages 53-63.
Crossref
Crossref
Guangping Li, Yuxuan Wang, Yan Shen, Haiqiong Guo, Qingxiu He, Yong Hu, Haibin Liu, Zhihua Lin & Yuanqiang Wang. (2021) In silico design of antimicrobial oligopeptides based on 3D-QSAR modeling and bioassay evaluation. Medicinal Chemistry Research.
Crossref
Crossref
Anne‐Marie Wegeberg, Theresa Meldgaard, Amanda Bæk, Asbjørn Mohr Drewes, Mogens Vyberg, Niels Jessen, Birgitte Brock & Christina Brock. (2021) Subcutaneous adipose tissue composition and function are unaffected by liraglutide‐induced weight loss in adults with type 1 diabetes. Basic & Clinical Pharmacology & Toxicology 128:6, pages 773-782.
Crossref
Crossref
R. Loera‐Valencia, A. Cedazo‐Minguez, P.A. Kenigsberg, G. Page, A.I. Duarte, P. Giusti, M. Zusso, P. Robert, G. B. Frisoni, Annamaria Cattaneo, M. Zille, J. Boltze, N. Cartier, L. Buee, G. Johansson & B. Winblad. (2019) Current and emerging avenues for Alzheimer's disease drug targets. Journal of Internal Medicine 286:4, pages 398-437.
Crossref
Crossref
D. Velmurugan, N. H. V. Kutumbarao, V. Viswanathan & Atanu Bhattacharjee. 2019. Structural Bioinformatics: Applications in Preclinical Drug Discovery Process. Structural Bioinformatics: Applications in Preclinical Drug Discovery Process
271
305
.
Chris de Graaf, Dan Donnelly, Denise Wootten, Jesper Lau, Patrick M. Sexton, Laurence J. Miller, Jung-Mo Ahn, Jiayu Liao, Madeleine M. Fletcher, Dehua Yang, Alastair J. H. Brown, Caihong Zhou, Jiejie Deng & Ming-Wei Wang. (2016) Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes. Pharmacological Reviews 68:4, pages 954-1013.
Crossref
Crossref
Åsa Segerstolpe, Athanasia Palasantza, Pernilla Eliasson, Eva-Marie Andersson, Anne-Christine Andréasson, Xiaoyan Sun, Simone Picelli, Alan Sabirsh, Maryam Clausen, Magnus K. Bjursell, David M. Smith, Maria Kasper, Carina Ämmälä & Rickard Sandberg. (2016) Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes. Cell Metabolism 24:4, pages 593-607.
Crossref
Crossref
Mary-Kathleen Grams, Suzanne Dinsmore, Jennifer Goldman-Levine & R. Rebecca Couris. (2015) An Overview of Glycemic Goals and Medications Used to Manage Type 2 Diabetes. Nutrition Today 50:1, pages 40-48.
Crossref
Crossref
Liselotte Fransson, Cristiane dos Santos, Petra Wolbert, Åke Sjöholm, Alex Rafacho & Henrik Ortsäter. (2014) Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome. Diabetology & Metabolic Syndrome 6:1.
Crossref
Crossref
Debashis Nandy, Christopher Johnson, Rita Basu, Michael Joyner, Jason Brett, Claus Bo Svendsen & Ananda Basu. (2014) The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diabetes and Vascular Disease Research 11:6, pages 419-430.
Crossref
Crossref
K. Stanley. (2014) Prader-Willi syndrome and hyperphagia: an update. Advances in Mental Health and Intellectual Disabilities 8:5, pages 321-330.
Crossref
Crossref
Susan E. Northfield, Conan K. Wang, Christina I. Schroeder, Thomas Durek, Meng-Wei Kan, Joakim E. Swedberg & David J. Craik. (2014) Disulfide-rich macrocyclic peptides as templates in drug design. European Journal of Medicinal Chemistry 77, pages 248-257.
Crossref
Crossref
Boon Chin HengDominique Aubel & Martin Fussenegger. (2014) G Protein–Coupled Receptors Revisited: Therapeutic Applications Inspired by Synthetic Biology. Annual Review of Pharmacology and Toxicology 54:1, pages 227-249.
Crossref
Crossref
Niclas Abrahamsson, Britt Edén Engström, Magnus Sundbom & F Anders Karlsson. (2013) GLP1 analogs as treatment of postprandial hypoglycemia following gastric bypass surgery: a potential new indication?. European Journal of Endocrinology 169:6, pages 885-889.
Crossref
Crossref
Boon Chin Heng, Dominique Aubel & Martin Fussenegger. (2013) An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases. Biotechnology Advances 31:8, pages 1676-1694.
Crossref
Crossref
Yao Dai, Jawahar L. Mehta & Mingwei Chen. (2013) Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation. Cardiovascular Drugs and Therapy 27:5, pages 371-380.
Crossref
Crossref
. (2013) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 20:2, pages 156-160.
Crossref
Crossref
Susan L. Samson & Alan Garber. (2013) GLP-1R agonist therapy for diabetes. Current Opinion in Endocrinology, Diabetes & Obesity 20:2, pages 87-97.
Crossref
Crossref
David J. Craik, David P. Fairlie, Spiros Liras & David Price. (2013) The Future of Peptide-based Drugs. Chemical Biology & Drug Design 81:1, pages 136-147.
Crossref
Crossref
Kiran S. Panickar. (2012) Effects of dietary polyphenols on neuroregulatory factors and pathways that mediate food intake and energy regulation in obesity. Molecular Nutrition & Food Research 57:1, pages 34-47.
Crossref
Crossref